Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.26

+1.2%

Nov 11 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (20665)	7/28/2006 10:48:11 AM
From: NeuroInvestment	Read Replies (5) of 52153

Not to get into the stroke topic too far, but I think the vascular route to intervention--clot-busting, has limited upside once the treatment window is expanded. At the moment there is a lot of potential just because so few patients qualify for tPA--but finetuning thrombolytics once one gets a decent post-stroke tx window (as DSPA seems to have) is not exciting. The reason is that achieving reperfusion alone does not address two issues: 1) the damage done during the hours of no blood flow; 2) the oxidative damage done by the process of reperfusion itself. Eventually, they have to juxtapose the vascular tx with something that operates on the neuronal side to provide protection. NXY-059 MAY be a first-generation version of that, Enecadin (or others) could eventually be better, second generation protectants. Harry NeuroInvestment

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next